Latest news with #hemodialysis
Yahoo
4 days ago
- Health
- Yahoo
12-year-old sworn in as honorary sheriff ahead of organ transplant
A 12-year-old New York boy who has kidney failure was sworn in as an honorary sheriff this week. Suffolk County Sheriff Errol D. Toulon Jr. oversaw the swearing-in ceremony of Wyatt Houppert on Tuesday, calling it an important event for everyone at the sheriff's office. "Welcoming Wyatt Houppert as 'Sheriff for the Day' was a meaningful moment for our agency," Toulon said in a statement to "Good Morning America." Son of sheriff's deputy sworn in on the same force as late father Wyatt's mom, Devan Houppert, told "GMA" they found out in 2021 that Wyatt was born with one regular kidney and another "the size of a walnut" that "had never developed." Houppert said doctors told them that over the years, Wyatt's one full-size kidney began to fail, and by February 2025, they learned both of Wyatt's kidneys had gone into failure, and he needed to be treated with hemodialysis and would eventually require a kidney transplant. According to the National Institute of Diabetes and Digestive and Kidney Diseases, hemodialysis is a treatment that helps the body filter water and waste from the bloodstream because the kidneys are unable to do so by themselves. Despite having to undergo dialysis three to four times a week for at least four hours per session, Houppert said her son has not lost hope and has kept a positive outlook for months. "Never for a second did he even consider it's not going to be OK," Houppert said. "It's always, 'We got this. Come on, let's just do it. Where's my kidney? Let's go right now.' And just so positive, just, 'It's going to be OK.'" "Many times, me and my husband have been upset sitting there, and then we're looking at him, going, 'Wait a second, we have so much to learn from this child,'" she added. "Because he's sitting there with the best attitude." Houppert said Dawn Rice, a family friend, volunteered to get evaluated to see if she could donate a kidney to Wyatt, and after testing, she said doctors surprised the family with the news that Rice was "a perfect match" for Wyatt. Rice also happens to be the wife and sister of two corrections officers with the Suffolk County Sheriff's Office, which honored her as well at Wyatt's "sheriff for the day" ceremony. "[Wyatt's] strength and courage are truly inspiring, and the selfless kidney donation by Dawn Rice reflects the compassion and unity of our Sheriff's Office family," Toulon said. 6-year-old with heart condition sworn in as honorary police officer Houppert said her 12-year-old was "over the moon" to be "sheriff for the day." "He's a very, like, stoic, serious guy. So when you get those smiles, and he's telling you, 'It's the best day ever,' you know that it really was," Houppert recalled. "He definitely took his sheriff duties very seriously all day," she added. "It was so funny hearing him telling his older brother, 'Turn the TV up. I'm the sheriff. We have to get pizza for dinner. I'm the sheriff.'" Wyatt is scheduled to undergo his kidney transplant at Hassenfeld Children's Hospital at NYU Langone in New York City on Monday. Dr. Marissa Lipton, a pediatric nephrologist in the Pediatric Kidney Transplant Program at Hassenfeld Children's Hospital, told "GMA" the kidney transplant will be life-changing for the boy. "Wyatt is an incredible kid with a wonderfully supportive family and community behind him. Our entire team at Hassenfeld Children's Hospital at NYU Langone is honored to care for him and support his family as he prepares for his transplant on Monday," Lipton said in an emailed statement. "We're looking forward to getting him off dialysis. This transplant will truly change his life, and we're so grateful to his living donor for this incredible gift," Lipton added. "We can't wait to see Wyatt back to playing outside and enjoying his video games like any active 12-year-old." Solve the daily Crossword
Globe and Mail
17-07-2025
- Business
- Globe and Mail
Rockwell Medical to Release Second Quarter 2025 Results on Thursday, August 14, 2025
Rockwell Medical, Inc. (the "Company") (Nasdaq: RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that it will release its financial and operational results for the second quarter ended June 30, 2025 on Thursday, August 14, 2025. The Company will issue a press release at 6:00am ET followed by a live conference call and webcast at 8:00am ET. CONFERENCE CALL AND WEBCAST DETAILS Date: Thursday, August 14, 2025 Time: 8:00am ET Live Number: (888) 660-6347 // (International) 1 (929) 201-6594 Conference Call ID: 4944610 Webcast and Replay: Speakers: Mark Strobeck, Ph.D. — President and Chief Executive Officer; and Jesse Neri — SVP, Chief Financial Officer Tim Chole — SVP, Chief Commercial Officer Format: Discussion of second quarter 2025 financial and operational results followed by Q&A. About Rockwell Medical Rockwell Medical, Inc. (Nasdaq: RMTI) is a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products for dialysis providers worldwide. Rockwell Medical's mission is to provide dialysis clinics and the patients they serve with the highest quality products supported by the best customer service in the industry. Rockwell is focused on innovative, long-term growth strategies that enhance its products, its processes, and its people, enabling the Company to deliver exceptional value to the healthcare system and provide a positive impact on the lives of hemodialysis patients. Hemodialysis is the most common form of end-stage kidney disease treatment and is typically performed at freestanding outpatient dialysis centers, hospital-based outpatient centers, skilled nursing facilities, or in a patient's home. Rockwell Medical's products are vital to vulnerable patients with end-stage kidney disease, and the Company is relentless in providing unmatched reliability and customer service. Certified as a Great Place to Work ® in 2023, 2024 and 2025, and named Fortune Best Workplaces in Manufacturing & Production TM in 2024, Rockwell Medical is Driven to Deliver Life-Sustaining Dialysis Solutions TM. For more information, visit
Yahoo
17-07-2025
- Business
- Yahoo
Rockwell Medical to Release Second Quarter 2025 Results on Thursday, August 14, 2025
WIXOM, Mich., July 17, 2025--(BUSINESS WIRE)--Rockwell Medical, Inc. (the "Company") (Nasdaq: RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that it will release its financial and operational results for the second quarter ended June 30, 2025 on Thursday, August 14, 2025. The Company will issue a press release at 6:00am ET followed by a live conference call and webcast at 8:00am ET. CONFERENCE CALL AND WEBCAST DETAILS Date: Thursday, August 14, 2025 Time: 8:00am ET Live Number: (888) 660-6347 // (International) 1 (929) 201-6594 Conference Call ID: 4944610 Webcast and Replay: Speakers: Mark Strobeck, Ph.D. — President and Chief Executive Officer; and Jesse Neri — SVP, Chief Financial Officer Tim Chole — SVP, Chief Commercial Officer Format: Discussion of second quarter 2025 financial and operational results followed by Q&A. About Rockwell Medical Rockwell Medical, Inc. (Nasdaq: RMTI) is a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products for dialysis providers worldwide. Rockwell Medical's mission is to provide dialysis clinics and the patients they serve with the highest quality products supported by the best customer service in the industry. Rockwell is focused on innovative, long-term growth strategies that enhance its products, its processes, and its people, enabling the Company to deliver exceptional value to the healthcare system and provide a positive impact on the lives of hemodialysis patients. Hemodialysis is the most common form of end-stage kidney disease treatment and is typically performed at freestanding outpatient dialysis centers, hospital-based outpatient centers, skilled nursing facilities, or in a patient's home. Rockwell Medical's products are vital to vulnerable patients with end-stage kidney disease, and the Company is relentless in providing unmatched reliability and customer service. Certified as a Great Place to Work® in 2023, 2024 and 2025, and named Fortune Best Workplaces in Manufacturing & ProductionTM in 2024, Rockwell Medical is Driven to Deliver Life-Sustaining Dialysis SolutionsTM. For more information, visit View source version on Contacts Heather R. HunterSVP, Chief Corporate Affairs Officer(248) 432-1362IR@ Sign in to access your portfolio
Yahoo
08-07-2025
- Business
- Yahoo
Rockwell Medical and Innovative Renal Care Announce Three-Year Partnership Agreement to Ensure Supply Chain Continuity of Quality Hemodialysis Products
WIXOM, Mich. & FRANKLIN, Tenn., July 08, 2025--(BUSINESS WIRE)--Rockwell Medical, Inc. (Nasdaq: RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, and Innovative Renal Care (IRC), one of the largest dialysis service providers in the United States, today announced they signed a multi-year service agreement to support IRC's goals to invest in high-quality hemodialysis products, streamline workflows, and help avoid potential supply chain disruptions. Under the terms of the agreement, Rockwell Medical will supply IRC with liquid and dry, acid and bicarbonate hemodialysis concentrates, as well as the DAMX45 dry acid concentrate mix system, which is 510(k) approved to be used exclusively with Rockwell Medical's CitraPure® and Dri-Sate® dry acid concentrate powders. This will enable IRC's dialysis centers across the United States to reduce storage requirements while ensuring product quality and continuity. This multi-million dollar purchase agreement with utilization commitments will remain in effect for three years with the option to extend an additional one-year period. "We are excited to partner with Rockwell Medical to reliably supply our clinics with hemodialysis concentrates," said David Doerr, Chief Executive Officer at IRC. "More efficient processes and supply chain continuity enables us to stay focused on achieving our company's mission to deliver more tomorrows to our patients, their families, and friends." "IRC is a comprehensive renal care company paving the way for innovative solutions to treat and manage patients with, or at high-risk of, end-stage renal disease," said Tim Chole, Senior Vice President and Chief Commercial Officer at Rockwell Medical. "We are excited to expand our supply agreement with IRC and build upon our long-standing reputation for a reliable supply chain, high-quality products, and excellent customer service." About Innovative Renal Care Innovative Renal Care (IRC) is a national leader in kidney care, partnering with nephrologists and health systems to provide exceptional care for patients with chronic kidney disease and end-stage renal disease. Through joint ventures and an innovative, collaborative model, IRC empowers local care teams with the tools, technology, and support to deliver industry-leading clinical outcomes and elevate the patient experience. Guided by our commitment to Delivering More Tomorrows, IRC stands apart as a trusted partner in advancing kidney care—one patient, one partnership, and one outcome at a time. To learn more, visit About Rockwell Medical Rockwell Medical, Inc. (Nasdaq: RMTI) is a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products for dialysis providers worldwide. Rockwell Medical's mission is to provide dialysis clinics and the patients they serve with the highest quality products supported by the best customer service in the industry. Rockwell is focused on innovative, long-term growth strategies that enhance its products, its processes, and its people, enabling the Company to deliver exceptional value to the healthcare system and provide a positive impact on the lives of hemodialysis patients. Hemodialysis is the most common form of end-stage kidney disease treatment and is typically performed in freestanding outpatient dialysis centers, hospital-based outpatient centers, skilled nursing facilities, or a patient's home. Rockwell Medical's products are vital to vulnerable patients with end-stage kidney disease, and the Company is relentless in providing unmatched reliability and customer service. Certified as a Great Place to Work® in 2023, 2024 and 2025, and named Fortune Best Workplaces in Manufacturing & Production™ in 2024, Rockwell Medical is Driven to Deliver Life-Sustaining Dialysis Solutions™. For more information, visit Forward-Looking Statements Certain statements in this press release may constitute "forward-looking statements" within the meaning of the federal securities laws. Words such as, "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "could," "can," "would," "develop," "plan," "potential," "predict," "forecast," "project," "intend," "look forward to," "remain confident," "are determined," "are on track," "are resolute in our vision," "work to," "drive towards," "focused on," or the negative of these terms, and similar expressions, or statements regarding intent, belief, or current expectations, are forward looking statements. While Rockwell Medical believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties (including, without limitation, those set forth in Rockwell Medical's SEC filings), many of which are beyond our control and subject to change. Actual results could be materially different. Risks and uncertainties include, but are not limited to those risks more fully discussed in the "Risk Factors" section of our Annual Report on Form 10-K for the year ended December 31, 2024, as such description may be amended or updated in any future reports we file with the SEC. Rockwell Medical expressly disclaims any obligation to update our forward-looking statements, except as may be required by law. View source version on Contacts Rockwell Medical, Inc. Heather R. HunterSVP, Chief Corporate Affairs Officer(248) 432-1362IR@ Innovative Renal Care Amanda ReedVP, Marketing & Communications(321) Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
13-05-2025
- Business
- Yahoo
Rockwell Medical Inc (RMTI) Q1 2025 Earnings Call Highlights: Navigating Challenges and ...
Net Sales: $18.9 million, a 17% decrease from $22.7 million in Q1 2024. Gross Profit: $3 million, consistent with the same period in 2024. Gross Margin: 16%, up from 14% in Q1 2024. Net Loss: $1.5 million, improved from a net loss of $1.7 million in Q1 2024. Adjusted EBITDA: Negative $400,000. Cash, Cash Equivalents, and Investments: $17.3 million as of March 31, 2025, down from $21.6 million at December 31, 2024. Projected 2025 Net Sales Guidance: Between $65 million and $70 million. Projected 2025 Gross Margin Guidance: Between 16% and 18%. Projected 2025 Adjusted EBITDA Guidance: Between negative $500,000 and positive $500,000. Warning! GuruFocus has detected 3 Warning Signs with RMTI. Release Date: May 12, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Rockwell Medical Inc (NASDAQ:RMTI) successfully diversified its customer base by signing new contracts with leading regional, national, and global hemodialysis providers. The company maintained its gross margin within the guidance range for the year, demonstrating effective cost management. Rockwell Medical Inc (NASDAQ:RMTI) launched a new single-use bicarbonate cartridge technology, expanding its product portfolio and addressing a growing market segment. The company is actively pursuing business development opportunities that could strengthen its position in the renal market and provide access to new markets. Rockwell Medical Inc (NASDAQ:RMTI) reiterated its projected guidance for 2025, indicating confidence in achieving net sales between $65 million and $70 million. Net sales for the first quarter decreased by 17% compared to the same period in 2024, primarily due to the largest customer transitioning to another supplier. The company experienced a net loss of $1.5 million for Q1 2025, although this was an improvement over the previous year's loss. Adjusted EBITDA for Q1 2025 was negative $400,000, impacted by seasonal items associated with payroll tax and other expenses. Cash, cash equivalents, and investments decreased from $21.6 million at the end of 2024 to $17.3 million at the end of Q1 2025. The ongoing negotiations with the largest customer may result in a scaled-down contractual commitment, potentially impacting future revenue. Q: Can you provide an update on the negotiations with your largest historical customer and the potential scenarios that could arise from these discussions? Also, what is the expected revenue cadence for the remainder of 2025? A: Discussions with our largest customer are ongoing to maintain some level of service, likely at a smaller scale than before. We aim to establish a long-term arrangement to supply them, including replenishing their safety stock. Regarding revenue, we are in the process of acquiring new customers, which could be significant. We are confident in our guidance and expect Q2 to be the low point for the year, with improvements thereafter. Q: Could you comment on the at-home dialysis market and your specific product offerings in this area? A: The at-home dialysis market is progressing as expected and is growing. Our product offering for this market is gaining traction, and we anticipate increased sales in the second half of the year. This product not only improves patient experience but also offers higher margins for us. Q: Can you provide more information on your international market expansion, particularly on the West Coast? A: We are expanding primarily in Latin America, which presents significant opportunities. For the West Coast of the U.S., we see potential as it is largely supported by one manufacturer. We are considering establishing a facility there to capitalize on this opportunity, but no final decisions have been made yet. Q: How do you plan to mitigate the revenue loss from your largest customer transitioning to another supplier? A: We believe there are enough opportunities among small independent dialysis providers and within our existing footprint to replace a significant portion of the lost revenue. Our focus is on expanding our customer base domestically and internationally, particularly in Latin America. Q: Is the revenue guidance you reaffirmed today based on your current customer base, and could new customers provide potential upside? A: Yes, the guidance is based on our current customer base. Any new customers acquired during the year would provide potential upside to our revenue projections. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus.
